Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Written informed consent obtained from the patient/legal representative~* Histologically confirmed recurrent or metastatic SCCHN~* Tumor progression or recurrence during or after treatment with only 1 systemic palliative regimen for recurrent or metastatic disease that must have contained a platinum agent.~* Written consent to provide newly acquired tumor tissue (preferred) or archival tissue for the purpose of establishing PD-L1 status.~* Confirmed PD-L1-positive SCCHN by Ventana SP263 assay~* WHO/ECOG performance status of 0 or 1~* At least 1 measurable lesion at baseline~* No prior exposure to immune-mediated therapy~* Adequate organ and marrow function~* Evidence of post-menopausal status or negative urinary or serum pregnancy test.~Exclusion Criteria:~* Histologically confirmed squamous cell carcinoma of any other primary anatomic location in the head and neck~* Received more than 1 systematic palliative regimen for recurrent or metastatic disease~* Any concurrent chemotherapy, Investigational Product, biologic, or hormonal therapy for cancer treatment~* Prior randomization or treatment in a previous MEDI4736 and/or tremelimumab clinical study regardless of treatment arm assignment or receipt of any investigational anticancer therapy within 28 days or 5 half-lives~* Receipt of last dose of an approved (marketed) anticancer therapy (chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the first dose of study treatment~* Major surgical procedure within 28 days prior to the first dose of Investigational Product~* Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criterion~* Current or prior use of immunosuppressive medication within 14 days before the first dose of MEDI4736~* History of allogeneic organ transplantation~* Active or prior documented autoimmune or inflammatory disorders;~* Uncontrolled intercurrent illness~* Another primary malignancy~* Patients with history of brain metastases, spinal cord compression, or leptomeningeal carcinomatosis~* History of active primary immunodeficiency~* Known history of previous tuberculosis~* Active infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV)~* Receipt of live, attenuated vaccine within 30 days prior to the first dose of MEDI4736~* Pregnant or breast-feeding female patients~* Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia's Correction~* Any condition that, in the opinion of the Investigator, would interfere with evaluation of the IP or interpretation of patient safety or study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- MEDI4736 (Type: EXPERIMENTAL): MEDI4736 monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete